Last reviewed · How we verify
BST-236
At a glance
| Generic name | BST-236 |
|---|---|
| Also known as | Aspacytarabine |
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS (PHASE2)
- Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy (PHASE2)
- A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML (PHASE1, PHASE2)
- Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS (PHASE2)
- Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BST-236 CI brief — competitive landscape report
- BST-236 updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI